NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:NPSP
- CUSIP: 62936P10
- Web: www.npsp.com
- 50 Day Moving Avg: $46.00
- 200 Day Moving Avg: $37.00
- 52 Week Range: $22.00 - $46.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 23.00
- P/E Growth: 0
- Net Margins: -2.96%
- Return on Equity: -5.98%
- Return on Assets: -2.77%
- Average Volume: 3.74 million shs.
Frequently Asked Questions for NPS Pharmaceuticals (NASDAQ:NPSP)
What is NPS Pharmaceuticals' stock symbol?
NPS Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."
How were NPS Pharmaceuticals' earnings last quarter?
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) released its quarterly earnings data on Wednesday, February, 18th. The company reported ($0.02) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.06 by $0.08. The company had revenue of $66.70 million for the quarter, compared to analyst estimates of $69.30 million. NPS Pharmaceuticals had a negative return on equity of 5.98% and a negative net margin of 2.96%. View NPS Pharmaceuticals' Earnings History.
Who are some of NPS Pharmaceuticals' key competitors?
Some companies that are related to NPS Pharmaceuticals include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), BeiGene (BGNE), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH) and China Biologic Products (CBPO).
How do I buy NPS Pharmaceuticals stock?
Shares of NPS Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NPS Pharmaceuticals' stock price today?
MarketBeat Community Rating for NPS Pharmaceuticals (NASDAQ NPSP)MarketBeat's community ratings are surveys of what our community members think about NPS Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of NPS Pharmaceuticals stock can currently be purchased for approximately $46.00.
Consensus Ratings for NPS Pharmaceuticals (NASDAQ:NPSP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for NPS Pharmaceuticals (NASDAQ:NPSP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for NPS Pharmaceuticals (NASDAQ:NPSP)Earnings History by Quarter for NPS Pharmaceuticals (NASDAQ NPSP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/18/2015||Q414||$0.06||($0.02)||$69.30 million||$66.70 million||View||N/A|
|11/10/2014||Q314||$0.01||($0.02)||$59.50 million||$57.20 million||View||N/A|
|8/6/2014||Q214||($0.01)||$0.02||$53.06 million||$56.10 million||View||Listen|
|5/8/2014||Q114||($0.04)||($0.06)||$48.30 million||$44.04 million||View||Listen|
|2/18/2014||Q413||$0.02||$0.07||$44.22 million||$54.45 million||View||Listen|
|8/8/2013||Q2 2013||($0.07)||($0.13)||$31.62 million||$36.50 million||View||Listen|
|5/9/2013||Q1 2013||($0.13)||($0.09)||$27.56 million||$25.43 million||View||Listen|
|2/21/2013||Q4 2012||($0.09)||($0.14)||$28.93 million||$27.10 million||View||Listen|
|11/9/2012||Q312||($0.16)||($0.04)||$28.18 million||$27.02 million||View||N/A|
Earnings Estimates for NPS Pharmaceuticals (NASDAQ:NPSP)
Current Year EPS Consensus Estimate: $1 EPS
Next Year EPS Consensus Estimate: $2 EPS
Dividend History for NPS Pharmaceuticals (NASDAQ:NPSP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NPS Pharmaceuticals (NASDAQ:NPSP)Insider Trades by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/10/2015||Susan E Graf||VP||Sell||6,711||$45.87||$307,833.57|| |
|12/17/2014||Joseph J Rogus||SVP||Sell||16,467||$35.00||$576,345.00|| |
|12/17/2014||Luke M Beshar||CFO||Sell||52,258||$35.00||$1,829,030.00|| |
|12/17/2014||Rachel R Selisker||Director||Sell||3,708||$34.59||$128,259.72|| |
|12/8/2014||Rachel R Selisker||Director||Sell||23,157||$34.50||$798,916.50|| |
|11/28/2014||Rachel R Selisker||Director||Sell||11,635||$34.50||$401,407.50|| |
|11/17/2014||Joseph J Rogus||SVP||Sell||26,782||$30.00||$803,460.00|| |
|11/11/2014||Rachel R Selisker||Director||Sell||15,188||$29.50||$448,046.00|| |
|10/31/2014||Luke M Beshar||CFO||Sell||10,000||$29.00||$290,000.00|| |
|10/27/2014||Luke M Beshar||CFO||Sell||30,635||$26.75||$819,486.25|| |
|2/13/2014||Georges Gemayel||Director||Sell||6,188||$37.70||$233,287.60|| |
|1/8/2014||Luke Beshar||CFO||Sell||31,588||$35.01||$1,105,895.88|| |
|12/26/2013||Luke Beshar||CFO||Sell||37,874||$30.02||$1,136,977.48|| |
|12/23/2013||James Groninger||Director||Sell||3,000||$29.50||$88,500.00|| |
|12/18/2013||Ed Stratemeier||SVP||Sell||205,432||$25.13||$5,162,506.16|| |
|9/20/2013||Luke Beshar||CFO||Sell||50,000||$30.26||$1,513,000.00|| |
|9/16/2013||Joseph Rogus||VP||Sell||25,312||$28.11||$711,520.32|| |
|9/16/2013||Luke Beshar||CFO||Sell||50,000||$27.89||$1,394,500.00|| |
|8/30/2013||Roger Garceau||CMO||Sell||110,000||$25.18||$2,769,800.00|| |
|8/20/2013||James Groninger||Director||Sell||16,900||$23.21||$392,249.00|| |
|5/9/2013||Luke M Beshar||CFO||Sell||45,150||$14.18||$640,227.00|| |
|11/15/2012||Glenn R Melrose||SVP||Buy||11,000||$9.09||$99,990.00|| |
|10/3/2012||Roger Garceau||CMO||Sell||140,625||$9.51||$1,337,343.75|| |
Headline Trends for NPS Pharmaceuticals (NASDAQ:NPSP)
Latest Headlines for NPS Pharmaceuticals (NASDAQ:NPSP)
NPS Pharmaceuticals (NPSP) Chart for Monday, July, 24, 2017